David Williams ^Leaders

David Williams is a highly successful CEO and entrepreneurial leader in the biopharmaceutical sector, bringing over 35 years of experience in large Pharma and Biotech. As the CEO of Sulantrix, he demonstrates a deep scientific and commercial understanding of bringing new drugs to patients and building investor value, with a track record of three successful RoI exits. Williams is known for his firm vision and expertise in building company infrastructures to support research portfolios across various disease areas, including inflammation, CNS, oncology, metabolic and immunological diseases, anti-virals, and anti-bacterials. His extensive experience spans all stages of research, from target discovery and translational research to clinical studies and commercial return. Williams possesses outstanding communication skills honed through interactions with the investor community and diverse international collaborations. Instrumental in bringing in Biotech deals valued at over $5B, he has co-founded several disruptive companies, including Sulantrix in 2022. Prior to his entrepreneurial ventures, Williams co-founded Nanna Therapeutics (sold to Astellas Pharma in 2020), Discuva (sold to Summit plc in 2017), and Sareum (IPO’d in 2004). His journey includes major roles in senior management and research at Summit plc, Millennium Pharmaceuticals, Medivir, Acambis, and Roche. Sulantrix, under Williams' leadership, is dedicated to translating exceptional science into transformational therapeutics, contributing to the evolution of innovative healthcare solutions.